{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:43:05Z","timestamp":1768635785231,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008858.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000}}],"reference-count":122,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008858.pub4","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:27:03Z","timestamp":1573126023000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Vaccines for preventing herpes zoster in older adults"],"prefix":"10.1002","volume":"2019","author":[{"given":"Anna MZ","family":"Gagliardi","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Department of Geriatrics and Gerontology; Rua Professor Francisco de Castro 105 S\u00e3o Paulo S\u00e3o Paulo Brazil 04020-050"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda NG","family":"Andriolo","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Regina","family":"Torloni","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo GO","family":"Soares","sequence":"additional","affiliation":[{"name":"Brazilian Cochrane Centre; Alameda Itu 1025\/ 42 S\u00e3o Paulo S\u00e3o Paulo Brazil 01421-001"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"de Oliveira Gomes","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Department of Geriatrics and Gerontology; Rua Professor Francisco de Castro 105 S\u00e3o Paulo S\u00e3o Paulo Brazil 04020-050"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis B","family":"Andriolo","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Par\u00e1; Department of Public Health; Travessa Perebebu\u00ed, 2623 Bel\u00e9m Par\u00e1 Brazil 66087-670"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Canteiro Cruz","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Department of Geriatrics and Gerontology; Rua Professor Francisco de Castro 105 S\u00e3o Paulo S\u00e3o Paulo Brazil 04020-050"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD008858.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1473-3099(16)00133-X","article-title":"Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial","volume":"16","author":"Beals","year":"2016","journal-title":"Lancet Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008858.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/514265","article-title":"A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older","volume":"178","author":"Berger","year":"1998","journal-title":"Journal of Infectious Diseases"},{"issue":"16","key":"10.1002\/14651858.CD008858.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0264-410X(99)00510-1","article-title":"Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial","volume":"18","author":"Trannoy","year":"2000","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1953-61","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01 adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u2265 50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"15","key":"10.1002\/14651858.CD008858.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.11150\/kansenshogakuzasshi.92.103","article-title":"Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old","volume":"92","author":"Ikematsu","year":"2018","journal-title":"Kansenshogaku Zasshi"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.vaccine.2014.12.024","article-title":"Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged \u2265 50 years: a randomised non-inferiority clinical trial","volume":"33","author":"Diez-Domingo","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl","key":"10.1002\/14651858.CD008858.pub4-BIB0009|cit9","first-page":"81-141","article-title":"A clinical study of a shingles (herpes zoster) vaccine (live) administered by intramuscular or subcutaneous routes in adults aged \u2265 50 years","volume":"4","author":"Diez-Domingo","year":"2013","journal-title":"European Geriatric Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clinical and Vaccine Immunology"},{"issue":"8","key":"10.1002\/14651858.CD008858.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1094-101","DOI":"10.1111\/dme.13038","article-title":"Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Hata","year":"2016","journal-title":"Diabetes and Metabolism"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"issue":"25","key":"10.1002\/14651858.CD008858.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/S0264-410X(99)00552-6","article-title":"Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older","volume":"18","author":"Levin","year":"2000","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2017.08.029","article-title":"Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine","volume":"36","author":"Levin","year":"2018","journal-title":"Vaccine"},{"issue":"29","key":"10.1002\/14651858.CD008858.pub4-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u2265 50 years of age: randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"issue":"25","key":"10.1002\/14651858.CD008858.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1016\/j.vaccine.2010.04.003","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster","volume":"28","author":"Mills","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4161\/hv.7.11.17982","article-title":"Safety and tolerability of zoster vaccine in adults \u2265 60 years old","volume":"7","author":"Murray","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0019|cit19","unstructured":"NCT00886613 A study to evaluate immunity to varicella zoster virus after immunization with V212 vaccine or zostavax (V212-003) clinicaltrials.gov\/ct2\/show\/NCT00886613"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0020|cit20","unstructured":"NCT01505647 Safety and immunogenicity of zoster vaccine (ZOSTAVAX\u2122) made with an alternative manufacturing process (AMP) (V211-042 AM1) clinicaltrials.gov\/ct2\/show\/study\/NCT01505647"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0021|cit21","unstructured":"NCT02052596 Immunogenicity and safety study of GSK Biologicals' herpes zoster vaccine GSK1437173A when co-administered with Boostrix\u00ae in adults aged 50 years and older clinicaltrials.gov\/ct2\/show\/study\/NCT02052596"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub4-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"Journal of the American Geriatrics Society"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1320-8","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub4-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"Journal of Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub4-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults \u2265 50 years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u2265 60 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1-7","DOI":"10.4161\/hv.23412","article-title":"Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax\u00ae) in individuals aged \u2265 70 years. A randomized study of a single dose vs. two different two-dose schedules","volume":"9","author":"Vesikari","year":"2013","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub4-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/21645515.2016.1232787","article-title":"Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged \u2265 50 years when administered subcutaneously vs. intramuscularly","volume":"13","author":"Vink","year":"2017","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/vim.1994.7.31","article-title":"Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults","volume":"7","author":"Hayward","year":"1994","journal-title":"Viral Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/vim.1996.9.241","article-title":"Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine","volume":"9","author":"Hayward","year":"1996","journal-title":"Viral Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.532-5415.2007.01109.x","article-title":"Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi","volume":"55","author":"Irwin","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub4-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"issue":"12","key":"10.1002\/14651858.CD008858.pub4-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2018.02.029","article-title":"Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials","volume":"36","author":"Kovac","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1002\/14651858.CD008858.pub4-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1280-90","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"Journal of Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.vaccine.2006.11.011","article-title":"Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults","volume":"25","author":"Macaladad","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults \u2265 60 years old","volume":"6","author":"MacIntyre","year":"2010","journal-title":"Human Vaccines"},{"issue":"41","key":"10.1002\/14651858.CD008858.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1016\/j.vaccine.2007.07.051","article-title":"Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine","volume":"25","author":"Patterson-Bartlett","year":"2007","journal-title":"Vaccine"},{"issue":"48 Part B","key":"10.1002\/14651858.CD008858.pub4-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1016\/j.vaccine.2017.10.017","article-title":"A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ\/su","volume":"35","author":"Strezova","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008858.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/infdis\/jiy383","article-title":"Comparative immune responses to licensed herpes zoster vaccines","volume":"218","author":"Weinberg","year":"2018","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0044|cit44","unstructured":"NCT02180295 A lot-to-lot consistency study to evaluate safety, tolerability, and immunogenicity of inactivated varicella zoster virus (VZV) vaccine in healthy adults (V212-014) clinicaltrials.gov\/ct2\/show\/NCT02180295"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0045|cit45","unstructured":"NCT02526745 Safety and immunogenicity study of live attenuated vaccine against herpes zoster in Chinese adults aged 50 years and older clinicaltrials.gov\/ct2\/show\/NCT02526745"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0046|cit46","unstructured":"NCT03116594 Immunogenicity and safety of two lots of NBP608 compared to Zostavax in healthy adult aged 50 and over clinicaltrials.gov\/ct2\/show\/NCT03116594"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0047|cit47","unstructured":"NCT03120364 Immunogenicity and safety of NBP608 compared to Zostavax in healthy adult aged 50 and over clinicaltrials.gov\/ct2\/show\/NCT03120364"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0048|cit48","unstructured":"NCT03439657 Immunogenicity and safety study of GSK Biologicals' herpes zoster vaccine GSK1437173A when co-administered with Prevnar 13 in adults aged 50 years and older clinicaltrials.gov\/ct2\/show\/NCT03439657"},{"issue":"13","key":"10.1002\/14651858.CD008858.pub4-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"1198-204","DOI":"10.1177\/0961203309345730","article-title":"Transverse myelitis and vaccines: a multi-analysis","volume":"18","author":"Agmon-Levin","year":"2009","journal-title":"Lupus"},{"issue":"19","key":"10.1002\/14651858.CD008858.pub4-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1903-15","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"New England Jounal of Medicine"},{"issue":"40","key":"10.1002\/14651858.CD008858.pub4-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11606\/S1518-8787.2018052000384","article-title":"Adverse events of vaccines and the consequences of non-vaccination: a critical review","volume":"52","author":"Aps","year":"2018","journal-title":"Revista Saude Publica"},{"issue":"22","key":"10.1002\/14651858.CD008858.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Ageing, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4049\/jimmunol.137.4.1346","article-title":"Immunity to varicella-zoster viral glycoproteins, gp I (gp 90\/58) and gp III (gp 118), and to a nonglycosylated protein, p 170","volume":"137","author":"Arvin","year":"1986","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clinical Microbiology Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2006.06.005","article-title":"The catastrophic antiphospholipid (Asherson's) syndrome","volume":"6","author":"Asherson","year":"2006","journal-title":"Autoimmunity Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD008858.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/BOR.0b013e32833a43c3","article-title":"The new H1N1 and HPV vaccines and old fears","volume":"22","author":"Balofsky","year":"2010","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.vaccine.2007.10.051","article-title":"Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly","volume":"26","author":"Bruijn","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12879-019-3691-2","article-title":"Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort","volume":"19","author":"Caputo","year":"2019","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0061|cit61","unstructured":"Centers for Disease Control, shingles vaccination www.cdc.gov\/vaccines\/vpd\/shingles\/public\/shingrix\/index.html"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jdermsci.2006.11.004","article-title":"Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea","volume":"45","author":"Cho","year":"2007","journal-title":"Journal of Dermatological Science"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"e2195","DOI":"10.1097\/MD.0000000000002195","article-title":"The incidence and risk of herpes zoster in patients with sleep disorders: a population-based cohort study","volume":"95","author":"Chung","year":"2016","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0064|cit64","first-page":"2773","article-title":"Varicella-zoster virus replication, pathogenesis, and management","volume-title":"Fields\u2019 Virology","author":"Cohen","year":"2007"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub4-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub4-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1086\/368196","article-title":"Treatment and prevention of postherpetic neuralgia","volume":"36","author":"Dworkin","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0067|cit67","unstructured":"USA FDA approval letter - Zostavax, 25 May 2006 https:\/\/wayback.archive-it.org\/7993\/20170723093336\/https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm132873.htm"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0068|cit68","unstructured":"USA FDA approval letter - zoster vaccine recombinant, adjuvanted. 20 October 2017 www.fda.gov\/downloads\/biologicsblood vaccines\/vaccines\/approvedproducts\/ucm581750.pdf"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0069|cit69","unstructured":"USA FDA approval letter - Zostavax www.fda.gov\/vaccines-blood-biologics\/vaccines\/zostavax"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Review of Vaccines"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jmv.21748","article-title":"No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia","volume":"82","author":"Gatti","year":"2010","journal-title":"Journal of Medical Virology"},{"issue":"9","key":"10.1002\/14651858.CD008858.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"635-45","DOI":"10.1056\/NEJM200003023420906","article-title":"Neurologic complications of the reactivation of varicella zoster virus","volume":"342","author":"Gilden","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1002\/14651858.CD008858.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice: herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0075|cit75","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"144-56","DOI":"10.1002\/path.2104","article-title":"Immunosenescence of ageing","volume":"211","author":"Gruver","year":"2007","journal-title":"Journal of Pathology"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.7326\/ACPJC-2006-144-1-A08","article-title":"An emerging consensus on grading recommendations?","volume":"144","author":"Guyatt","year":"2006","journal-title":"ACP Journal Club"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/00365540110077218","article-title":"Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster","volume":"34","author":"Haanp\u00e4\u00e4","year":"2002","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2015.02.005","article-title":"Revisiting adverse reactions to vaccines: a critical appraisal of autoimmune syndrome induced by adjuvants (ASIA)","volume":"59","author":"Hawkes","year":"2015","journal-title":"Journal of Autoimmunity"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s15010-007-6347-x","article-title":"Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel","volume":"36","author":"Heymann","year":"2008","journal-title":"Infection"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archderm.144.5.603","article-title":"Family history as a risk factor for herpes zoster: a case-control study","volume":"144","author":"Hicks","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"7414","key":"10.1002\/14651858.CD008858.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0084|cit84","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"103","DOI":"10.11150\/kansenshogakuzasshi.92.103","article-title":"Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old","volume":"92","author":"Ikematsu","year":"2018","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BioMed Central Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2340\/00015555-0729","article-title":"Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006","volume":"89","author":"Jih","year":"2009","journal-title":"Acta Dermato-Venereologica"},{"issue":"16","key":"10.1002\/14651858.CD008858.pub4-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub4-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"221-6","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of herpes zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molinacortex","volume":"146","author":"Kensil","year":"1991","journal-title":"Journal of Immunology"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e81823","DOI":"10.1371\/journal.pone.0081823","article-title":"Publication bias in recent meta-analyses","volume":"8","author":"Kicinski","year":"2013","journal-title":"PLOS ONE"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLOS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0300-8932(97)73190-7","article-title":"Investigation methods in clinical cardiology (IV) clinical measurements in cardiology: validity and errors of measurement","volume":"50","author":"Latour","year":"1997","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub4-BIB0095|cit95","first-page":"681","article-title":"Severe autoimmune adverse events post herpes zoster vaccine: a case-control study of adverse events in a national database","volume":"14","author":"Lai","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5411\/wji.v5.i2.62","article-title":"Epigenomic revolution in autoimmune diseases","volume":"5","author":"Dantec","year":"2015","journal-title":"World Journal of Immunology"},{"issue":"11","key":"10.1002\/14651858.CD008858.pub4-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1046\/j.1365-3156.1998.00316.x","article-title":"Review of varicella zoster soroepidemiology in India and South-East Asia","volume":"3","author":"Lee","year":"1998","journal-title":"Tropical Medicine & International Health"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0098|cit98","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/bjc.1993.402","article-title":"Intention to treat - who should use ITT?","volume":"68","author":"Lewis","year":"1993","journal-title":"British Journal of Cancer"},{"issue":"February","key":"10.1002\/14651858.CD008858.pub4-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","article-title":"Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain","volume":"167","author":"Mareque","year":"2019","journal-title":"Public Health"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12879-016-1898-z","article-title":"Increasing incidence associated with herpes zoster infection in British Columbia, Canada","volume":"16","author":"Marra","year":"2016","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0102|cit102","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.038","article-title":"Pathogenesis and the disease consequences of primary infection","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Moffat","year":"2007"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0103|cit103","unstructured":"SK Chemicals receives permission to market shingles vaccine http:\/\/english.hani.co.kr\/arti\/english_edition\/e_business\/813943.html"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub4-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD008858.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/14656560902808502","article-title":"The treatment of varicella-zoster virus infection and its complications","volume":"10","author":"Partridge","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"December","key":"10.1002\/14651858.CD008858.pub4-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2013.10.004","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects","volume":"47","author":"Perricone","year":"2013","journal-title":"Journal of Autoimmunity"},{"issue":"4","key":"10.1002\/14651858.CD008858.pub4-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"397-402","DOI":"10.1111\/j.1533-2500.2010.00432.x","article-title":"Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly","volume":"11","author":"Pickering","year":"2011","journal-title":"Pain Practice"},{"issue":"14","key":"10.1002\/14651858.CD008858.pub4-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1263-76","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines - current status, problems and future prospects","volume":"13","author":"Rajesh","year":"1995","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0109|cit109","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan) 2014"},{"issue":"7","key":"10.1002\/14651858.CD008858.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/651078","article-title":"Increasing incidence of herpes zoster among veterans","volume":"50","author":"Rimland","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/10489140-000000000-00000","article-title":"Zoster vaccine (Zostavax\u00ae) a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults","volume":"27","author":"Sanford","year":"2010","journal-title":"Drugs and Aging"},{"issue":"6","key":"10.1002\/14651858.CD008858.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"Herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clinical Journal of Pain"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub4-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"1320-8","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008858.pub4-BIB0115|cit115","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD008858.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infectious Diseases"},{"issue":"8173","key":"10.1002\/14651858.CD008858.pub4-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"k4029","DOI":"10.1136\/bmj.k4029","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","volume":"363","author":"Tricco","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008858.pub4-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10067-017-3748-9","article-title":"The autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)\/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry","volume":"37","author":"Watad","year":"2018","journal-title":"Clinical Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD008858.pub4-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008858","article-title":"Vaccines for preventing herpes zoster in older adults","author":"Gagliardi","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008858.pub4-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008858.pub2","article-title":"Vaccines for preventing herpes zoster in older adults","author":"Gagliardi","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008858.pub4-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008858.pub3","article-title":"Vaccines for preventing herpes zoster in older adults","author":"Gagliardi","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008858.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008858.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:53:27Z","timestamp":1695398007000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008858.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":122,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008858.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008858.pub5","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]}}}